Aaron G.l. Fletcher - 31 Mar 2022 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
Director
Signature
/s/ Aaron Fletcher by Colin Sandercock, attorney-in-fact
Issuer symbol
CUE
Transactions as of
31 Mar 2022
Net transactions value
+$3,498,600
Form type
4
Filing time
04 Apr 2022, 17:28:54 UTC
Previous filing
01 Feb 2022
Next filing
04 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CUE Common Stock Purchase $3,498,600 +735,000 $4.76 735,000 31 Mar 2022 See footnote F1
holding CUE Common Stock 165,000 31 Mar 2022 Direct
holding CUE Common Stock 8,867 31 Mar 2022 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund, LP. Aaron Fletcher is the manager of Bios Advisors GP, LLC, the general partner of Bios Capital Management, L.P., the general partner of Bios Equity SOF I, LP, the general partner of Bios Special Opportunity Fund, LP.